Evaluating the economic screening of cervical cancer using IVA, HPV DNA, and histology methods: Systematic review
DOI:
https://doi.org/10.31101/jhtam.3255Keywords:
Cervical Cancer, HPV DNA, VIA, Cytology, ICERAbstract
Background: Cervical cancer is a common malignancy causing cancer-related deaths worldwide. Evidence suggests that adequate screening can reduce cervical cancer-related deaths. Screening for cervical cancer can be done using Visual Inspection of Acetic Acid (VIA), HPV DNA and cytology. The economic burden of cancer patients is substantial ranging from US$8,066 to 22,888 per patient. Health cost effectiveness was comparative in the analysis of costs and consequences for the three screening methods. VIA is the most cost-effective primary screening test for cervical cancer. Purpose: To review the research results of a full economic evaluation to encourage the specific cervical cancer screening methods used to enhance the detection of precancerous lesions in women's cervix. Method: This systematic review used the PRISMA ScR framework with a literature search using 3 databases, namely Pubmed, Wiley, and Google Scholar, with years of publication from 2009 – 2023. The data that has been obtained is carried out by critical appraisal using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS). Results: Based on the search for 3,973 selected articles, 7 match the inclusion criteria. This systematic review discovered three major themes: the utility value of health status, cost and analysis. Conclusion: The most cost-effective cervical cancer screening is by VIA. HPV DNA and pap smear based cytology techniques have been reported to show high sensitivity and specificity respectively including being expensive and resource intensive. In contrast the VIA technique has moderate sensitivity and specificity but is less expensive Various developed countries have used Pap or HPV DNA cytology tests as the main screening method, which can lead to a 50-70% reduction in cervical cancer incidence, while in developing countries using VIA tests as a cervical cancer screening method.References
Auliya. (2022). Economic evaluation and HTA : Concept and best practices in Indoesia. Health Economics Book Series.
Boardman. (2019). Cervical Cancer.
Chandigarh, S. of P. H. P. I. of M. E. & R. (2022). Health Technology Assessment of Strategies for Cervical Cancer Screening in India.
Chauhan. (2020). Cost Effectiveness of Strategies For Cervical Cancer Prevention in India. PLoS ONE, 15(9).
Chauhan, A. S., Prinja, S., Srinivasan, R., Rai, B., Malliga, J. S., Jyani, G., Gupta, N., & Ghoshal, S. (2020). Cost Effectiveness of Strategies For Cervical Cancer Prevention in India. PLoS ONE, 15(9 September). https://doi.org/10.1371/journal.pone.0238291
Chow. (2010). Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed healthcare system. British Journal of Cancer, 1773–1782. https://doi.org/doi: 10.1038/sj.bjc.6605974
Chow, I. H., Tang, C., You, S., Liao, C., Chu, T., Chen, C., Chen, C., & Pwu, R. (2010). Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system. British Journal of Cancer, 1773–1782. https://doi.org/10.1038/sj.bjc.6605974
Cromwell, Smith, Hoek, van der, Hedden, Coldman, & Cook. (2021). Cost-efectiveness analysis of primary human papillomavirus testing in cervical cancer screening: results from the HPV FOCAL Trial. Cancer Med, 10(9), 2996–3003.
Don Husereau. (2022). Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value in Health, 25(1), 10–31.
Huy, Tam, Tram, Thuan, Vihn, & Than. (2019). The value of visual inspection with acetic acid and Pap smear in cervical cancer screening program in low resource settings - a population-based study. Gynaecol Oncol Reports, 24(1), 18–20. https://doi.org/10.1016/j.gore.2018.02.004.
Irham. (2023). Quality of Life of Cancer Patients during Chemotherapy in Indonesia: A Comparison of EORTC QLQ-C30 and EQ-5D-5L. Based on Patients’ Characteristics.
Kulasingam, S. L., Rajan, R., Pierre, Y. S., Atwood, V., Myers, E. R., & Franco, E. L. (2009). Human Papillomavirus Testing with Pap Triage for Cervical Cancer Prevention in Canada : a Cost-Effectiveness Analysis. 11, 1–11. https://doi.org/10.1186/1741-7015-7-69
Lewandowska, Rudzki, Lewandowski, Próchnicki, Rudzki, Laskowska, & Brudniak. (2020). Quality of Life of Cancer Patients Treated with Chemotherapy. International Journal of Environmental Research and Public Health, 17(19), 69–83. https://doi.org/10.3390/ijerph17196938
Rosmalen, J. Van, Kok, I. De, & Ballegooijen, M. Van. (2012). Cost-Effectiveness of Cervical Cancer Screening : Cytology Versus Human Papillomavirus DNA Testing. 699–709. https://doi.org/10.1111/j.1471-0528.2011.03228.x
Rosmalen, Van, Kok, De, & Ballegooijen. (2012). ‘Cost-Effectiveness of Cervical Cancer Screening : Cytology Versus Human Papillomavirus DNA Testing.
Shi. (2011). ‘Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China : an epidemiologic and cost-effectiveness modelling study’.
Shi, J., Canfell, K., Lew, J., Zhao, F., Legood, R., Ning, Y., Simonella, L., Ma, L., Kang, Y., Zhang, Y., Smith, M. A., Chen, J., & Feng, X. (2011). Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China : an epidemiologic and cost-effectiveness modelling study.
Termrungruanglert. (2017a). ‘Cost-effectiveness analysis study of HPV testing as a primary cervical cancer screening in Thailand’, Gynecologic Oncology Reports, 22(September). https://doi.org/doi: 10.1016/j.gore.2017.09.007.
Termrungruanglert. (2017b). ‘Cost-effectiveness analysis study of HPV testing as a primary cervical cancer screening in Thailand’, Gynecologic Oncology Reports.
Tricco, A. C., Lillie, E., Zarin, W., O’Brien, K. K., Colquhoun, H., Levac, D., Moher, D., Peters, M. D. J., Horsley, T., Weeks, L., Hempel, S., Akl, E. A., Chang, C., McGowan, J., Stewart, L., Hartling, L., Aldcroft, A., Wilson, M. G., Garritty, C., … Straus, S. E. (2018). Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist SECTION. Ann Intern Med, 169(7), 11–12. https://doi.org/10.7326/M18-0850.2
Turner, Lauer, Tran, Teerawattananon, & Jit. (2019). Adjusting for infation and currency changes within health economic studies. Value Heal, 22(9), 1026–1032. https://doi.org/10.1016/j.jval.2019.03.021.
World Health Organization. (2019). A Draft : global strategy towards the elimination of.
World Health Organization. (2020). Global market study - HPV. Glob Mark Study.
World Health Organization. (2023). Cervical cancer. https://www.who.int/news-room/fact-sheets/detail/cervicalcancer?gclid=CjwKCAiA1fqrBhA1EiwAMU5m_xAF0VGf4z8QipY
QtwmS5O_kOdaWiQnwk79nF4HFFvHM_HnODv621hoC3PwQAvD_BwE
Wu, Jia, Chen, Zhang, Liu, & Prem. (2020). PLOS ONE The economic burden of cervical cancer from diagnosis to one year after fnal discharge in Henan province, China : a retrospective case series study. https://doi.org/10.1371/journal.pone.0232129
Wuriningsih, A. ., & Distinarista, H. (2019). Servical Cancer Self Management Education(CSME) Meningkatkan Kualitas Hidup Pasien dengan Kanker Serviks. Jurnal Keperawatan Dan Pemikiran Ilmiah, 5(6), 45–51.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Ana Rofika, Desi Ratnasari , Indah Christiana , Okta Zenita Siti Fatimah, ST. Mukarromah, Mufdillah, Putri Listiani
![Creative Commons License](http://i.creativecommons.org/l/by-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with Journal of Health Technology Assessment in Midwifery agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Journal of Health Technology Assessment in Midwifery is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License..